-
Mashup Score: 2Home - 7 hour(s) ago
Activity Overview
Source: na.eventscloud.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 18Tumor Suppressor Gene Signature Predicts Early Progression in mHSPC - Marta Garcia de Herreros - 7 day(s) ago
Neeraj Agarwal interviews Marta Garcia de Herreros about presentation on tumor suppressor gene (TSG) signatures in metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Garcia de Herreros discusses the TSG-low signature, based on low expression of RB1, PTEN, and TP53 genes, which predicts early progression to castration-resistant prostate cancer (CRPC) and the development of aggressive…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Tumor suppressor gene signature predicts early progression in #mHSPC. @MartaGdeH & @neerajaiims discuss clinical implications, the need for more frequent monitoring, patient counseling, and potential treatment strategies for pts with TSG-low signatures > https://t.co/M4Rtf5sRlO https://t.co/njIoO9thxJ
-
-
Mashup Score: 2
Evan Y. Yu, MD, discusses how individualized first-line systemic therapy selection for metastatic hormone-sensitive prostate cancer (mHSPC) involves considering factors such as disease burden, patient performance status, and comorbidities while weighing the pros and cons of current options—such as chemotherapy-sparing regimens, androgen receptor pathway inhibitor (ARPI) selection, and the use of triplet versus doublet combination therapies—to optimize efficacy and minimize adverse effects based on each patient’s unique clinical profile.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
Newly Diagnosed #mHSPC: Androgen Receptor Pathway Inhibitor Selection | @UWDeptMedicine https://t.co/eC8rahU9IJ
-
-
Mashup Score: 18Tumor Suppressor Gene Signature Predicts Early Progression in mHSPC - Marta Garcia de Herreros - 1 month(s) ago
Neeraj Agarwal interviews Marta Garcia de Herreros about presentation on tumor suppressor gene (TSG) signatures in metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Garcia de Herreros discusses the TSG-low signature, based on low expression of RB1, PTEN, and TP53 genes, which predicts early progression to castration-resistant prostate cancer (CRPC) and the development of aggressive…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Tumor suppressor gene signature predicts early progression in #mHSPC. @MartaGdeH & @neerajaiims discuss clinical implications, the need for more frequent monitoring, patient counseling, and potential treatment strategies for pts with TSG-low signatures > https://t.co/M4Rtf5sRlO https://t.co/njIoO9thxJ
-
-
Mashup Score: 2Coordinating Complex Care in High-Volume mHSPC Through Multidisciplinary Communication - Jonathan Henderson & Sunil Kakadia - 2 month(s) ago
Alicia Morgans convenes a discussion on managing high-volume metastatic hormone-sensitive prostate cancer, bridging the practices of urology and medical oncology with Jonathan Henderson and Sunil Kakadia, a medical oncologist from Genesis Oncology. They emphasize the importance of collaborative care in treating complex cases, like a patient presenting with high PSA levels, highlighting the…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Coordinating complex care in high-volume #mHSPC through multidisciplinary communication. Jonathan Henderson, MD @ArUrology & Sunil Kakadia, MD, MPH, FACP join @CaPsurvivorship @DanaFarber in this discussion on managing high-volume mHSPC > https://t.co/wB74NwGIJy https://t.co/eirLyGGyql
-
-
Mashup Score: 18Tumor Suppressor Gene Signature Predicts Early Progression in mHSPC - Marta Garcia de Herreros - 2 month(s) ago
Neeraj Agarwal interviews Marta Garcia de Herreros about presentation on tumor suppressor gene (TSG) signatures in metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Garcia de Herreros discusses the TSG-low signature, based on low expression of RB1, PTEN, and TP53 genes, which predicts early progression to castration-resistant prostate cancer (CRPC) and the development of aggressive…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Tumor suppressor gene signature predicts early progression in #mHSPC. @MartaGdeH & @neerajaiims discuss clinical implications, the need for more frequent monitoring, patient counseling, and potential treatment strategies for pts with TSG-low signatures > https://t.co/M4Rtf5sRlO https://t.co/njIoO9thxJ
-
-
Mashup Score: 2Coordinating Complex Care in High-Volume mHSPC Through Multidisciplinary Communication - Jonathan Henderson & Sunil Kakadia - 3 month(s) ago
Alicia Morgans convenes a discussion on managing high-volume metastatic hormone-sensitive prostate cancer, bridging the practices of urology and medical oncology with Jonathan Henderson and Sunil Kakadia, a medical oncologist from Genesis Oncology. They emphasize the importance of collaborative care in treating complex cases, like a patient presenting with high PSA levels, highlighting the…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Coordinating complex care in high-volume #mHSPC through multidisciplinary communication. Jonathan Henderson, MD @ArUrology & Sunil Kakadia, MD, MPH, FACP join @CaPsurvivorship @DanaFarber in this discussion on managing high-volume mHSPC > https://t.co/wB74NwGIJy https://t.co/eirLyGGyql
-
-
Mashup Score: 5
Alicia Morgans speaks with Mary-Ellen Taplin about strategies for managing metastatic hormone-sensitive prostate cancer (mHSPC) patients who do not achieve optimal PSA declines. Dr. Taplin emphasizes that an unfavorable PSA decline is not synonymous with progression and highlights the prognostic value of achieving a PSA nadir below 0.2. She discusses data from various trials, such as SWOG 9346,…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Escalation strategies for suboptimal PSA decline in #mHSPC. Mary-Ellen Taplin, MD @DanaFarber joins @CaPsurvivorship to discuss managing mHSPC patients who do not achieve optimal PSA declines > https://t.co/tNfpLBly8Y https://t.co/tIYIaWUpyG
-
-
Mashup Score: 9Prognostic and Predictive Factors in Metastatic Hormone-Sensitive Prostate Cancer - Matthew Smith - 3 month(s) ago
Alicia Morgans speaks with Matthew Smith about prognostic and predictive factors in treating metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Smith explains the importance of clinical, imaging, and molecular factors in patient selection for treatment intensification. He highlights that factors like disease volume, manner of presentation, and specific genomic alterations (e.g., PTEN,…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Prognostic and predictive factors in #mHSPC. Matthew Smith @MassGeneralNews and @CaPsurvivorship @DanaFarber discuss the importance of clinical, imaging, and molecular factors in patient selection for treatment intensification > https://t.co/jIDin3LspP https://t.co/48t7TP1kkJ
-
-
Mashup Score: 18Tumor Suppressor Gene Signature Predicts Early Progression in mHSPC - Marta Garcia de Herreros - 3 month(s) ago
Neeraj Agarwal interviews Marta Garcia de Herreros about presentation on tumor suppressor gene (TSG) signatures in metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Garcia de Herreros discusses the TSG-low signature, based on low expression of RB1, PTEN, and TP53 genes, which predicts early progression to castration-resistant prostate cancer (CRPC) and the development of aggressive…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Tumor suppressor gene signature predicts early progression in #mHSPC. @MartaGdeH & @neerajaiims discuss clinical implications, the need for more frequent monitoring, patient counseling, and potential treatment strategies for pts with TSG-low signatures > https://t.co/M4Rtf5sRlO https://t.co/njIoO9thxJ
-
🔬 Stay ahead with the latest clinical trial data on novel treatment strategies for mHSPC! 🤝 Enhance MDT collaboration to optimize care pathways & improve patient outcomes. 🔗 Learn more: https://t.co/Pu9YnzJTwZ #mHSPC @amerseburger @AlbertoBossial @Ecastromarcos https://t.co/Iolc2c6ZUM